

Xolair CSU - Home - MOP
Image



Image



Xolair[®]
(omalizumab)

Xolair® (omalizumab)

More information

Great Britain (GB) Summary of Product Characteristics (SmPC) for the [75 mg pre-filled syringe](#) and [autoinjector pen](#), [150 mg pre-filled syringe](#) and [autoinjector pen](#), and [300 mg pre-filled syringe](#) and [autoinjector pen](#) for Xolair.

Great Britain (GB) Patient Information Leaflet (PIL) for the [75 mg pre-filled syringe](#) and [autoinjector pen](#), [150 mg pre-filled syringe](#) and [autoinjector pen](#), and [300 mg pre-filled syringe](#) and [autoinjector pen](#) for Xolair.

These links will take you to the electronic medicines compendium Great Britain (emc) website, which is a non-Novartis website.

Northern Ireland (NI) Summary of Product Characteristics (SmPC) for the [75 mg pre-filled syringe and autoinjector pen](#), [150 mg pre-filled syringe and autoinjector pen](#), and [300 mg pre-filled syringe and autoinjector pen](#) for Xolair.

Northern Ireland (NI) Patient Information Leaflet (PIL) for the [75 mg pre-filled syringe](#) and [150 mg pre-filled syringe](#) for Xolair.

These links will take you to the electronic medicines compendium Northern Ireland (emc) website, which is a non-Novartis website.



Patient resources

Patient resources

See more details

Hide details

UK | October 2024 | FA-11221723

Reporting side-effects

If you get side-effects with any medication you are taking, talk to your doctor, pharmacist or nurse. This includes any possible side-effects not listed in the information leaflet that comes in the pack. You can report side-effects via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.

By reporting side-effects you can help provide more information on the safety of your medication.

Source URL: <https://www.pro.novartis.com/uk-en/public/medicines/dermatology/xolair>